As a proinflammatory cytokine that is expressed in primary tumors, IL-1B has been identified as a potential biomarker in patients with breast carcinoma (Martínez-Reza et al., 2019), IL-1B is highly expressed in the blood of patients with NSCLC (Kim et al., 2013), which was in consistency with the outcomes. This evidence concerns the gene IL1B and non-small cell lung carcinoma.